Payment overview · 2025
General Payments
$2,293.12
50 reported records · 13 companies
Healthcare provider profile · identity verified
Patrick Joseph Welch, M.D.
Allopathic & Osteopathic Physicians|General Practice · LAFAYETTE, LA · NPI 1417146283
Verified facts
What the public records show
CMS Open Payments records show Patrick Joseph Welch, M.D. received $2,293.12 in general payments during 2025 across 50 reported records.
Abbott Laboratories accounted for 61.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,418.93 | 61.9% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$149.51 | 6.5% | 8 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $148.20 | 6.5% | 7 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $118.85 | 5.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $115.68 | 5.0% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $95.01 | 4.1% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $88.30 | 3.9% | 5 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $38.91 | 1.7% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $36.77 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.04 | 1.1% | 1 | 2025 |
| Elutia, Inc. | Unresolved — no canonical attribution shown | $23.19 | 1.0% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.41 | 0.8% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $16.32 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,152.32 | 45 |
| Travel and Lodging | $1,140.80 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $1,369.29 | 11 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $118.85 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $90.21 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $88.30 | 5 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $71.25 | 2 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $56.37 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $51.68 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $50.42 | 2 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| Echelon; Endopath Normalized: echelon endopath |
Device | Ethicon US, LLC | $36.77 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $33.49 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $30.51 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $29.42 | 3 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| ECM Patch,Pouch Normalized: ecm patch pouch |
Device | Elutia, Inc. | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $7.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Flecainide Acetate | Flecainide Acetate | 1045 | 198 |
| Metoprolol Succinate | Metoprolol Succinate | 700 | 137 |
| Eliquis | Apixaban | 669 | 107 |
| Amiodarone Hcl | Amiodarone Hcl | 329 | 65 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 241 | 64 |
| Sotalol | Sotalol Hcl | 197 | 40 |
| Multaq | Dronedarone Hcl | 194 | 42 |
| Xarelto | Rivaroxaban | 129 | 29 |
| Tiadylt Er | Diltiazem Hcl | 88 | 13 |
| Potassium Chloride | Potassium Chloride | 84 | 14 |
| Carvedilol | Carvedilol | 74 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 70 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 63 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 39 |
| Verapamil Er | Verapamil Hcl | 45 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Losartan Potassium | Losartan Potassium | 25 | suppressed |
| Corlanor | Ivabradine Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Dofetilide | Dofetilide | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Matzim La | Diltiazem Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,293.12 · 50 records | Abbott Laboratories | AFFERA MAPPING SYSTEM, AMPLATZER AMULET, AMVIA EDGE, AURORA EV-ICD MRI SURESCAN, AVEIR, Acticor 7 VR-T DX, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, COBALT DR MRI SURESCAN, ECM Patch,Pouch, ENSITE, Echelon; Endopath, FARAPULSE, FLOWTRIEVER, INSPIRE, Kerecis GraftGuide, Kerecis SurgiClose, LINQ II, LifeVest, Optimizer, SELECTSECURE, Solia, WATCHMAN Access System, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error